A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.

Cited by (1,095)

Items 401–500 of 1,095

1. Real-world experience of esketamine use to manage treatment-resistant depression: A multicentric study on safety and effectiveness (REAL-ESK study)
   Martinotti, Giovanni, Vita, Antonio, Fagiolini, Andrea, Maina, Giuseppe, Bertolino, Alessandro, Dell'Osso, Bernardo, Siracusano, Alberto, Clerici, Massimo, Bellomo, Antonello, Sani, Gabriele et al. · 2022 · Journal of Affective Disorders
2. The role of mitochondria in mood disorders: from physiology to pathophysiology and to treatment
   Giménez-Palomo, Anna, Dodd, Seetal, Anmella, Gerard, Carvalho, Andre F., Scaini, Giselli, Quevedo, Joao, Pacchiarotti, Isabella, Vieta, Eduard, Berk, Michael · 2021 · Frontiers in Psychiatry
3. Dysfunctional hippocampal activity affects emotion and cognition in mood disorders
   Femenía, Teresa, Gómez-Galán, Marta, Lindskog, Maria, Magara, Salvatore · 2012 · Brain Research
4. Stress and VTA synapses: implications for addiction and depression
   Abigail M. Polter, Julie A. Kauer · 2014 · European Journal of Neuroscience
5. Ketamine—50 years in use: from anesthesia to rapid antidepressant effects and neurobiological mechanisms
   Samuel Kohtala · 2021 · Pharmacological Reports
6. Psychotherapeutic Benefits of Opioid Agonist Therapy
   Peter L. Tenore · 2008 · Journal of Addictive Diseases
7. NMDA receptors and metaplasticity: Mechanisms and possible roles in neuropsychiatric disorders
   Charles F. Zorumski, Yukitoshi Izumi · 2012 · Neuroscience & Biobehavioral Reviews
8. Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status
   Henter, Ioline D., Park, Lawrence T., Zarate, Carlos A. · 2021 · CNS Drugs
9. Treatment-resistant depression: are animal models of depression fit for purpose?
   Paul Willner, Catherine Belzung · 2015 · Psychopharmacology
10. Neurocognitive Effects of Ketamine and Association with Antidepressant Response in Individuals with Treatment-Resistant Depression: A Randomized Controlled Trial
    Murrough, James W, Burdick, Katherine E, Levitch, Cara F, Perez, Andrew M, Brallier, Jess W, Chang, Lee C, Foulkes, Alexandra, Charney, Dennis S, Mathew, Sanjay J, Iosifescu, Dan V · 2015 · Neuropsychopharmacology
11. Target Identification for CNS Diseases by Transcriptional Profiling
    C. Anthony Altar, Marquis P. Vawter, Stephen D. Ginsberg · 2008 · Neuropsychopharmacology
12. Inhibition of Glycine Transporter-I as a Novel Mechanism for the Treatment of Depression
    Chih‐Chia Huang, I‐Hua Wei, Chieh-Liang Huang, Kuang-Ti Chen, Mang‐Hung Tsai, Priscilla Tsai, Rene Tun, Kuo-Hao Huang, Yue‐Cune Chang, Hsien‐Yuan Lane et al. · 2013 · Biological Psychiatry
13. TrkB dependent adult hippocampal progenitor differentiation mediates sustained ketamine antidepressant response
    Zhenzhong Ma, Tong Zang, Shari G. Birnbaum, Zilai Wang, Jane E. B. Johnson, Chun‐Li Zhang, Luis F. Parada · 2017 · Nature Communications
14. Depressive Disorders in Epilepsy
    Andres Miguel Kanner · 2012 · Wiley eBooks
15. Efficacy and Safety of Ketamine vs Electroconvulsive Therapy Among Patients With Major Depressive Episode: A Systematic Review and Meta-analysis
    Rhee, Taeho Greg, Shim, Sung Ryul, Forester, Brent P., Nierenberg, Andrew A., McIntyre, Roger S., Papakostas, George I., Krystal, John H., Sanacora, Gerard, Wilkinson, Samuel T. · 2022 · JAMA Psychiatry
16. Neuropeptide and small transmitter coexistence: Fundamental studies and relevance to mental illness
    Hökfelt, Tomas, Barde, Swapnali, Xu, Zhi-Qing David, Kuteeva, Eugenia, Rüegg, Joelle, Le Maitre, Erwan, Risling, Mårten, Kehr, Jan, Ihnatko, Robert, Theodorsson, Elvar et al. · 2018 · Frontiers in Neural Circuits
17. Antidepressant, mood stabilizing and procognitive effects of very low dose sublingual ketamine in refractory unipolar and bipolar depression
    Diogo Rizzato Lara, Luísa Weber Bisol, Luciano R. Munari · 2013 · The International Journal of Neuropsychopharmacology
18. Serum BDNF as a peripheral biomarker of treatment-resistant depression and the rapid antidepressant response: A comparison of ketamine and ECT
    Allen, A.P., Naughton, M., Dowling, J., Walsh, A., Ismail, F., Shorten, G., Scott, L., McLoughlin, D.M., Cryan, J.F., Dinan, T.G. et al. · 2015 · Journal of Affective Disorders
19. Novel Therapeutic Targets in Depression and Anxiety: Antioxidants as a Candidate Treatment
    Ying Xu, Chuang Wang, Jonathan Klabnik, James O' Donnell · 2014 · Current Neuropharmacology
20. Ketamine as the prototype glutamatergic antidepressant: pharmacodynamic actions, and a systematic review and meta-analysis of efficacy
    Caroline Caddy, Giovanni Giaroli, Thomas P. White, Sukhwinder Singh Shergill, Derek Kenneth Tracy · 2013 · Therapeutic Advances in Psychopharmacology
21. Simultaneous population pharmacokinetic modelling of ketamine and three major metabolites in patients with treatment-resistant bipolar depression
    Zhao, Xiaochen, Venkata, Swarajya Lakshmi Vattem, Moaddel, Ruin, Luckenbaugh, Dave A., Brutsche, Nancy E., Ibrahim, Lobna, Zarate Jr, Carlos A., Mager, Donald E., Wainer, Irving W. · 2012 · British Journal of Clinical Pharmacology
22. Can neurobiological pathogenic mechanisms of depression facilitate the development of seizure disorders?
    Andres Miguel Kanner · 2012 · The Lancet Neurology
23. Overview of Glutamatergic Dysregulation in Central Pathologies
    Tanya Miladinovic, Mina G. Nashed, Gurmit Singh · 2015 · Biomolecules
24. Modulation of stress consequences by hippocampal monoaminergic, glutamatergic and nitrergic neurotransmitter systems
    Sâmia R.L. Joca, Frederico Rogério Ferreira, Francisco Silveira Guimarães · 2007 · Stress
25. Neurobiological Mechanisms of Stress Resilience and Implications for the Aged Population
    Charlène Faye, Josephine Cecelia McGowan, Christine Ann Denny, Denis Joseph Paul David · 2018 · Current Neuropharmacology
26. Altered Transcranial Magnetic Stimulation–Electroencephalographic Markers of Inhibition and Excitation in the Dorsolateral Prefrontal Cortex in Major Depressive Disorder
    Daphne Voineskos, Daniel M. Blumberger, Reza Zomorrodi, Nigel C. Rogasch, Faranak Farzan, George Foussias, Tarek K. Rajji, Zafiris Jeff Daskalakis · 2018 · Biological Psychiatry
27. Novel neuroimmunologic therapeutics in depression: A clinical perspective on what we know so far
    Roman, Michael, Irwin, Michael R. · 2020 · Brain, Behavior, and Immunity
28. Sex Differences in Effects of Ketamine on Behavior, Spine Density, and Synaptic Proteins in Socially Isolated Rats
    Ambalika Sarkar, Mohamed Kabbaj · 2016 · Biological Psychiatry
29. Molecular Pharmacology and Neurobiology of Rapid-Acting Antidepressants
    Gould, Todd D., Zarate, Carlos A., Thompson, Scott M. · 2019 · Annual Review of Pharmacology and Toxicology
30. Efficacy and Safety of Basimglurant as Adjunctive Therapy for Major Depression: A Randomized Clinical Trial
    Quiroz, Jorge A., Tamburri, Paul, Deptula, Dennis, Banken, Ludger, Beyer, Ulrich, Rabbia, Michael, Parkar, Nikhat, Fontoura, Paulo, Santarelli, Luca · 2016 · JAMA Psychiatry
31. Features of dissociation differentially predict antidepressant response to ketamine in treatment-resistant depression
    Mark J. Niciu, Bridget J. Shovestul, Brittany A. Jaso, Cristan Farmer, David A. Luckenbaugh, Nancy E. Brutsché, Lawrence T. Park, Elizabeth D. Ballard, Carlos A. Zarate · 2018 · Journal of Affective Disorders
32. The STAR*D Trial: Revealing the Need for Better Treatments
    Thomas R. Insel, Philip S. Wang · 2009 · Psychiatric Services
33. An update on ketamine and its two enantiomers as rapid-acting antidepressants
    Zhang, Kai, Hashimoto, Kenji · 2019 · Expert Review of Neurotherapeutics
34. Activation of Mammalian Target of Rapamycin and Synaptogenesis: Role in the Actions of Rapid-Acting Antidepressants
    Jason M. Dwyer, Ronald S. Duman · 2013 · Biological Psychiatry
35. Acute and chronic effects of NMDA receptor antagonists in rodents, relevance to negative symptoms of schizophrenia: A translational link to humans
    Joanna Caroline Neill, Michael Harte, Peter Michael Haddad, Emma S. Lydall, Dominic Michael Dwyer · 2013 · European Neuropsychopharmacology
36. Creatine, Similar to Ketamine, Counteracts Depressive-Like Behavior Induced by Corticosterone via PI3K/Akt/mTOR Pathway
    Francis L. Pazini, Mauricio Peña Cunha, Julia Macedo Rosa, André Roberto Da Silva Colla, Vicente Lieberknecht, Ágatha Oliveira‐Giacomelli, Ana Lúcia S. Rodrigues · 2015 · Molecular Neurobiology
37. Ketamine and Beyond: Investigations into the Potential of Glutamatergic Agents to Treat Depression
    Lener, Marc S., Kadriu, Bashkim, Zarate, Carlos A. · 2017 · Drugs
38. GLYX-13, an NMDA receptor glycine site functional partial agonist enhances cognition and produces antidepressant effects without the psychotomimetic side effects of NMDA receptor antagonists
    Joseph R. Moskal, Ronald M. Burch, Jeffrey S. Burgdorf, Roger A. Kroes, Patric K. Stanton, John F. Disterhoft, J. David Leander · 2013 · Expert Opinion on Investigational Drugs
39. Laminar and Cellular Distribution of Monoamine Receptors in Rat Medial Prefrontal Cortex
    Noemí Santana, Francesc Artigas · 2017 · Frontiers in Neuroanatomy
40. Learning from the past and looking to the future: emerging perspectives for improving the treatment of psychiatric disorders
    Millan, Mark J., Goodwin, Guy M., Meyer-Lindenberg, Andreas, Ove Ögren, Sven · 2015 · European Neuropsychopharmacology
41. Ketamine as a new treatment for depression: A review of its efficacy and adverse effects
    Natalie Katalinic, Rosalyn Lai, Andrew Alexander Somogyi, Philip Bowden Mitchell, Paul Glue, Colleen K A Loo · 2013 · Australian & New Zealand Journal of Psychiatry
42. Inhibition of GABA interneurons in the mPFC is sufficient and necessary for rapid antidepressant responses
    Fogaça, Manoela V., Wu, Min, Li, Chan, Li, Xiao-Yuan, Picciotto, Marina R., Duman, Ronald S. · 2021 · Molecular Psychiatry
43. Clinically favourable effects of ketamine as an anaesthetic for electroconvulsive therapy: a retrospective study
    Laura Kranaster, Jutta Kammerer-Ciernioch, Carolin Hoyer, Alexander Sartorius · 2011 · European Archives of Psychiatry and Clinical Neuroscience
44. Ketamine applications beyond anesthesia – A literature review
    Nowacka, Agata, Borczyk, Malgorzata · 2019 · European Journal of Pharmacology
45. A brief history of antidepressant drug development: from tricyclics to beyond ketamine
    Vitor Silva Pereira, Vinicius Sato · 2018 · Acta Neuropsychiatrica
46. A systematic review and meta-analysis of randomized controlled trials of adjunctive ketamine in electroconvulsive therapy: Efficacy and tolerability
    McGirr, Alexander, Berlim, Marcelo T., Bond, David J., Neufeld, Nicholas H., Chan, Peter Y., Yatham, Lakshmi N., Lam, Raymond W. · 2015 · Journal of Psychiatric Research
47. Reduction of dopamine D2/3 receptor binding in the striatum after a single administration of esketamine, but not R-ketamine: a PET study in conscious monkeys
    Hashimoto, Kenji, Kakiuchi, Takeharu, Ohba, Hiroyuki, Nishiyama, Shingo, Tsukada, Hideo · 2017 · European Archives of Psychiatry and Clinical Neuroscience
48. Antidepressants for people with epilepsy and depression
    Melissa Maguire, Jennifer Weston, Jasvinder A. Singh, Anthony Guy Marson · 2014 · Cochrane Database of Systematic Reviews
49. Sigma receptors: Potential targets for a new class of antidepressant drug
    James A. Fishback, Matthew James Robson, Yan‐Tong Xu, Rae R. Matsumoto · 2010 · Pharmacology & Therapeutics
50. Elevated gene expression of glutamate receptors in noradrenergic neurons from the locus coeruleus in major depression
    Michelle Chandley, Attila Szebeni, Katalin Szebeni, Jessica D. Crawford, Craig A. Stockmeier, Gustavo Turecki, Richard M. Kostrzewa, Gregory A. Ordway · 2014 · The International Journal of Neuropsychopharmacology
51. Comparison of (R)-ketamine and lanicemine on depression-like phenotype and abnormal composition of gut microbiota in a social defeat stress model
    Youge Qu, Chun Yang, Qian Ren, Min Ma, Chao Dong, Kenji Hashimoto · 2017 · Scientific Reports
52. The role of vitamin C in stress-related disorders
    Bettina Moritz, Ariana Ern Schmitz, Ana Lúcia S. Rodrigues, Alcir Luiz Dafré, Mauricio Peña Cunha · 2020 · The Journal of Nutritional Biochemistry
53. AMPA Receptor Activation–Independent Antidepressant Actions of Ketamine Metabolite (S)-Norketamine
    Chun Yang, Shizuka Kobayashi, Kazuhito Nakao, Chao Dong, Mei Han, Youge Qu, Qian Ren, Ji-chun Zhang, Min Ma, Hidetoh Toki et al. · 2018 · Biological Psychiatry
54. Therapeutic mechanisms of classic hallucinogens in the treatment of addictions: from indirect evidence to testable hypotheses
    Michael P. Bogenschutz, Jessica M. Pommy · 2012 · Drug Testing and Analysis
55. Review of Pharmacological Treatment in Mood Disorders and Future Directions for Drug Development
    Xiaohua Li, Mark A. Frye, Richard Charles Shelton · 2011 · Neuropsychopharmacology
56. The role of NMDA receptors in the pathophysiology and treatment of mood disorders
    Mehdi Ghasemi, Cristy Phillips, Ludwig Trillo, Zurine D. Miguel, Devsmita Das, Ahmad Salehi · 2014 · Neuroscience & Biobehavioral Reviews
57. Epilepsy coexisting with depression
    Barbara Błaszczyk, Stanisław Jerzy Czuczwar · 2016 · Pharmacological Reports
58. Ketamine accelerates fear extinction via mTORC1 signaling
    Matthew J. Girgenti, Sriparna Ghosal, Dora Lopresto, Jane R. Taylor, Ronald S. Duman · 2016 · Neurobiology of Disease
59. VGF function in depression and antidepressant efficacy
    Cheng Shi Jiang, W-J Lin, Masato Sadahiro, Benoît Labonté, Caroline Ménard, Madeline L. Pfau, Carol A. Tamminga, Gustavo Turecki, Eric J. Nestler, Scott J. Russo et al. · 2017 · Molecular Psychiatry
60. Dual Role of Autophagy in Diseases of the Central Nervous System
    Tamara Bar-Yosef, Odeya Damri, Galila Agam · 2019 · Frontiers in Cellular Neuroscience
61. Repeated Ketamine Exposure Induces an Enduring Resilient Phenotype in Adolescent and Adult Rats
    Eric M. Parise, Lyonna F. Parise, Brandon L. Warren, Katherine N. Wright, Roey Hadad, Omar K. Sial, Kyle G. Kroeck, Sergio D. Iñiguez, Carlos A. Bolaños‐Guzmán · 2013 · Biological Psychiatry
62. The acute antisuicidal effects of single-dose intravenous ketamine and intranasal esketamine in individuals with major depression and bipolar disorders: A systematic review and meta-analysis
    Xiong, Jiaqi, Lipsitz, Orly, Chen-Li, David, Rosenblat, Joshua D., Rodrigues, Nelson B., Carvalho, Isabelle, Lui, Leanna M.W., Gill, Hartej, Narsi, Flora, Mansur, Rodrigo B. et al. · 2021 · Journal of Psychiatric Research
63. Innovative solutions to novel drug development in mental health
    Insel, T.R., Voon, V., Nye, J.S., Brown, V.J., Altevogt, B.M., Bullmore, E.T., Goodwin, G.M., Howard, R.J., Kupfer, D.J., Malloch, G. et al. · 2013 · Neuroscience & Biobehavioral Reviews
64. Ketamine as a novel treatment for major depressive disorder and bipolar depression: a systematic review and quantitative meta-analysis
    Lee, Ellen E., Della Selva, Megan P., Liu, Anson, Himelhoch, Seth · 2015 · General Hospital Psychiatry
65. NMDAR-independent, cAMP-dependent antidepressant actions of ketamine
    Nathan H. Wray, Jeffrey M. Schappi, Harinder Singh, Nicolas B. Senese, Mark M. Rasenick · 2018 · Molecular Psychiatry
66. A randomised double blind trial of the effect of pre-emptive epidural ketamine on persistent pain after lower limb amputation
    John A. Wilson, Alastair F. Nimmo, Susan M. Fleetwood-Walker, Lesley Colvin · 2007 · Pain
67. The Integrative Management of Treatment-Resistant Depression: A Comprehensive Review and Perspectives
    Carvalho, Andre F., Berk, Michael, Hyphantis, Thomas N., McIntyre, Roger S. · 2014 · Psychotherapy and Psychosomatics
68. Transient stimulation with psychoplastogens is sufficient to initiate neuronal growth
    Ly, Calvin, Greb, Alexandra C., Vargas, Maxemiliano V., Duim, Whitney C., Grodzki, Ana Cristina G., Lein, Pamela J., Olson, David E. · 2021 · ACS Pharmacology & Translational Science
69. Therapeutic infusions of ketamine: do the psychoactive effects matter?
    Dakwar, E., Anerella, C., Hart, C.L., Levin, F.R., Mathew, S.J., Nunes, E.V. · 2014 · Drug and Alcohol Dependence
70. Oral Ketamine for the Rapid Treatment of Depression and Anxiety in Patients Receiving Hospice Care
    Irwin, Scott A., Iglewicz, Alana · 2010 · Journal of Palliative Medicine
71. KETAMINE FOR TREATMENT-RESISTANT UNIPOLAR AND BIPOLAR MAJOR DEPRESSION: CRITICAL REVIEW AND IMPLICATIONS FOR CLINICAL PRACTICE
    William Victor Bobo, Jennifer L. Vande Voort, Paul E. Croarkin, Jonathan G. Leung, Susannah J. Tye, Mark A. Frye · 2016 · Depression and Anxiety
72. Long-term safety of ketamine and esketamine in treatment of depression
    Sina Nikayin, Eva Murphy, John Harrison Krystal, Samuel T. Wilkinson · 2022 · Expert Opinion on Drug Safety
73. Elevated level of metabotropic glutamate receptor 2/3 in the prefrontal cortex in major depression
    Anteneh M. Feyissa, William L. Woolverton, José Javier Miguel-Hidalgo, Zhixia Wang, Patrick B. Kyle, Gregor Hasler, Craig A. Stockmeier, Abiye H. Iyo, Beata Karolewicz · 2009 · Progress in Neuro-Psychopharmacology and Biological Psychiatry
74. Ketamine amplifies induced gamma frequency oscillations in the human cerebral cortex
    Shaw, Alexander D., Saxena, Neeraj, E. Jackson, Laura, Hall, Judith E., Singh, Krish D., Muthukumaraswamy, Suresh D. · 2015 · European Neuropsychopharmacology
75. Rapid Antidepressant Action and Restoration of Excitatory Synaptic Strength After Chronic Stress by Negative Modulators of Alpha5-Containing GABAA Receptors
    Fischell, Jonathan, Van Dyke, Adam M, Kvarta, Mark D, LeGates, Tara A, Thompson, Scott M · 2015 · Neuropsychopharmacology
76. The molecular pathophysiology of depression and the new therapeutics
    Tian, Haihua, Hu, Zhenyu, Xu, Jia, Wang, Chuang · 2022 · MedComm
77. Ketamine enantiomers in the rapid and sustained antidepressant effects
    Muller, John, Pentyala, Sahana, Dilger, James, Pentyala, Srinivas · 2016 · Therapeutic Advances in Psychopharmacology
78. D-serine as a gliotransmitter and its roles in brain development and disease
    Marion R. Van Horn, Mari Sild, Edward S. Ruthazer · 2013 · Frontiers in Cellular Neuroscience
79. Cognitive Behavior Therapy May Sustain Antidepressant Effects of Intravenous Ketamine in Treatment-Resistant Depression
    Samuel T. Wilkinson, DaShaun Wright, Madonna K. Fasula, Lisa R. Fenton, Matthew Griepp, Robert B. Ostroff, Gerard Sanacora · 2017 · Psychotherapy and Psychosomatics
80. Chronic Administration of Ketamine Elicits Antidepressant‐Like Effects in Rats without Affecting Hippocampal Brain‐Derived Neurotrophic Factor Protein Levels
    Lêda Soares Brandão Garcia, Clarissa Martinelli Comim, Samira Silva Valvassori, Gislaine Z. Réus, Ana C. Andreazza, Laura Stertz, Gabriel R. Fries, Elaine Cristina Gavioli, Flávio Pereira Kapczinski, João Quevedo · 2008 · Basic & Clinical Pharmacology & Toxicology
81. Towards new mechanisms: an update on therapeutics for treatment-resistant major depressive disorder
    George I. Papakostas, D. Ionescu · 2015 · Molecular Psychiatry
82. Ketamine as a Potential Treatment for Suicidal Ideation: A Systematic Review of the Literature
    Reinstatler, Lael, Youssef, Nagy A. · 2015 · Drugs in R&D
83. How could stress lead to major depressive disorder?
    Gal Richter‐Levin, Lin Xu · 2018 · IBRO Reports
84. How antidepressant drugs act: A primer on neuroplasticity as the eventual mediator of antidepressant efficacy
    Chittaranjan Andrade, NSanjay Kumar Rao · 2010 · Indian Journal of Psychiatry
85. Essential role of microglial transforming growth factor-β1 in antidepressant actions of (R)-ketamine and the novel antidepressant TGF-β1
    Zhang, Kai, Yang, Chun, Chang, Lijia, Sakamoto, Akemi, Suzuki, Toru, Fujita, Yuko, Qu, Youge, Wang, Siming, Pu, Yaoyu, Tan, Yunfei et al. · 2020 · Translational Psychiatry
86. Ketamine as a promising prototype for a new generation of rapid‐acting antidepressants
    Abdallah, Chadi G., Averill, Lynnette A., Krystal, John H. · 2015 · Annals of the New York Academy of Sciences
87. A biological pathway linking inflammation and depression: activation of indoleamine 2,3-dioxygenase
    Davies, David M. Christmas, John P. Potokar · 2011 · Neuropsychiatric Disease and Treatment
88. Pharmacogenomics of antidepressant drugs
    Sonja Horstmann, Elisabeth B. Binder · 2009 · Pharmacology & Therapeutics
89. Rapid antidepressant actions of scopolamine: Role of medial prefrontal cortex and M1-subtype muscarinic acetylcholine receptors
    Navarria, Andrea, Wohleb, Eric S., Voleti, Bhavya, Ota, Kristie T., Dutheil, Sophie, Lepack, Ashley E., Dwyer, Jason M., Fuchikami, Manabu, Becker, Astrid, Drago, Filippo et al. · 2015 · Neurobiology of Disease
90. Setdb1 Histone Methyltransferase Regulates Mood-Related Behaviors and Expression of the NMDA Receptor Subunit NR2B
    Jiang, Yan, Jakovcevski, Mira, Bharadwaj, Rahul, Connor, Caroline, Schroeder, Frederick A., Lin, Cong L., Straubhaar, Juerg, Martin, Gilles, Akbarian, Schahram · 2010 · The Journal of Neuroscience
91. Targeting Glutamatergic Signaling for the Development of Novel Therapeutics for Mood Disorders
    Rodrigo Machado‐Vieira, Giacomo Salvadore, Lobna A. Ibrahim, Nancy Diazgranados, Carlos A. Zarate · 2009 · Current Pharmaceutical Design
92. Increased Glutamate Levels in the Medial Prefrontal Cortex in Patients with Postpartum Depression
    Alyssa M McEwen, Denee Burgess, Christopher C. Hanstock, Peter Seres, Panteha Khalili, Stephen C. Newman, Glen B. Baker, Nicholas Mitchell, Janisse Khudabux, Peter S. Allen et al. · 2012 · Neuropsychopharmacology
93. Neuropsychological and mood effects of ketamine in electroconvulsive therapy: A randomised controlled trial
    Colleen K A Loo, Natalie Katalinic, Joshua B. B. Garfield, Kirby Sainsbury, Dušan Hadži-Pavlović, Ross MacPherson · 2012 · Journal of Affective Disorders
94. Stress and excitatory synapses: From health to disease
    Wendy Timmermans, Hui Xiong, Casper C. Hoogenraad, Harm J. Krugers · 2013 · Neuroscience
95. Ketamine and its metabolite (2R,6R)-hydroxynorketamine induce lasting alterations in glutamatergic synaptic plasticity in the mesolimbic circuit
    Yao, N, Skiteva, O, Zhang, X, Svenningsson, P, Chergui, K · 2018 · Molecular Psychiatry
96. Potential role of the 5-HT6 receptor in depression and anxiety: an overview of preclinical data
    Anna Wesołowska · 2010 · Pharmacological Reports
97. Nine traditional Chinese herbal formulas for the treatment of depression: an ethnopharmacology, phytochemistry, and pharmacology review
    Yang Wang, Feng Dandan, Tao Tang, Xiangping Lin, Zhaoyu Yang, Shu Yang, Zian Xia, Yun Wang, Piao Zheng, Chunhu Zhang · 2016 · Neuropsychiatric Disease and Treatment
98. Ketamine: Mechanisms and Relevance to Treatment of Depression
    Ji‐Woon Kim, Kanzo Suzuki, Ege T. Kavalali, Lisa M. Monteggia · 2023 · Annual Review of Medicine
99. Psychiatric safety of ketamine in psychopharmacology research
    Perry, Edward B., Cramer, Joyce A., Cho, Hyun-Sang, Petrakis, Ismene L., Karper, Laurence P., Genovese, Angelina, O’Donnell, Elizabeth, Krystal, John H., D’Souza, D. Cyril, Yale Ketamine Study Group · 2007 · Psychopharmacology
100. Comparing the actions of lanicemine and ketamine in depression: key role of the anterior cingulate
     Downey, Darragh, Dutta, Arpan, McKie, Shane, Dawson, Gerard R., Dourish, Colin T., Craig, Kevin, Smith, Mark A., McCarthy, Dennis J., Harmer, Catherine J., Goodwin, Guy M. et al. · 2016 · European Neuropsychopharmacology